Cheng Jiang

Cheng Jiang


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
YZYong Zhang
Yong Zhang
YDYinhui Dong
Yinhui Dong
MMMichael W. Melkus
Michael W. Melkus
SYShutao Yin
Shutao Yin
STSu-Ni Tang
Su-Ni Tang
CJCheng Jiang
Cheng Jiang
Bufalin is a major cardiotonic compound in the traditional Chinese medicine, Chansu, prepared from toad skin secretions. Cell culture studies have suggested an anticancer potential involving multiple cellular processes, including differentiation, apoptosis, senescence, and angiogenesis. In prostate cancer cell models, P53-dependent and independent caspase-mediated apoptosis and androgen receptor (AR) antagonism have been described for bufalin at micromolar concentrations. Because a human pharmacokinetic study indicated that single nanomolar bufalin was safely achievable in the peripheral circulation, we evaluated its cellular activity within range with the AR-positive and P53 wild-type human LNCaP prostate cancer cells in vitro. Our data show that bufalin induced caspase-mediated apoptosis at 20 nmol/L or higher concentration with concomitant suppression of AR protein and its best-known target, PSA and steroid receptor coactivator 1 and 3 (SRC-1, SRC-3). Bufalin exposure induced protein abundance of P53 (not mRNA) and P21CIP1 (CDKN1A), G2 arrest, and increased senescence-like phenotype (SA-galactosidase). Small RNAi knocking down of P53 attenuated bufalin-induced senescence, whereas knocking down of P21CIP1 exacerbated bufalin-induced caspase-mediated apoptosis. In vivo, daily intraperitoneal injection of bufalin (1.5 mg/kg body weight) for 9 weeks delayed LNCaP subcutaneous xenograft tumor growth in NSG SCID mice with a 67% decrease of final weight without affecting body weight. Tumors from bufalin-treated mice exhibited increased phospho-P53 and SA-galactosidase without detectable caspase-mediated apoptosis or suppression of AR and PSA. Our data suggest potential applications of bufalin in therapy of prostate cancer in patients or chemo-interception of prostate precancerous lesions, engaging a selective activation of P53 senescence. Mol Cancer Ther; 17(11); 2341–52. ©2018 AACR.

1 November 1997 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
CJCheng Jiang
Cheng Jiang
LJL Juo
L Juo
TST K Said
T K Said
HTH Thompson
H Thompson
DMD Medina
D Medina
The acquisition of immortalization is an early and carefully documented event in mouse mammary tumorigenesis. Activation of telomerase activity is one hypothesis to explain the acquisition of immortalization. We examined the activity of telomerase in well-defined immortalized, non-tumor cell populations of mouse mammary tissue in vivo. The results indicated that normal virgin and mid-pregnant mammary gland had low to moderate levels of telomerase activity, respectively. In comparison with the levels detected in pregnant mammary gland, telomerase activity was elevated in mammary tumors in situ and in established mammary cell lines in vitro, both tumorigenic and nontumorigenic; however, hyperplastic alveolar preneoplastic mammary outgrowths and non-tumorigenic ductal outgrowths, both in vivo immortalized populations, had telomerase activity <12% of the levels detected in normal pregnant mammary gland. These results suggest that elevated telomerase activity is not necessary for the immortalization phenotype in in vivo mouse mammary cell populations and that elevated telomerase activity occurs as a late event in mammary tumorigenesis. Furthermore, the data suggest that low levels of telomerase activity are characteristic for mouse mammary epithelial cells and not sufficient for immortalization. These data suggest that other factors play more important roles in the induction and/or maintenance of the immortalization state in mammary cell populations.

22 August 2022 in The Prostate
Verified
Journal Article
Closed access
DKDeepkamal N. Karelia
Deepkamal N. Karelia
SKSangyub Kim
Sangyub Kim
Plano DanielPlano Daniel
Plano Daniel
Arun SharmaArun Sharma
Arun Sharma
CJCheng Jiang
Cheng Jiang
JLJunxuan Lu
Junxuan Lu

31 January 2024 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
DSDongxiao Sun
Dongxiao Sun
SKSangyub Kim
Sangyub Kim
DKDeepkamal Karelia
Deepkamal Karelia
YDYibin Deng
Yibin Deng
CJCheng Jiang
Cheng Jiang
JLJunxuan Lu
Junxuan Lu
Our previous work has shown a synergistic tumoricidal efficacy of combining the hexokinase (HK) inhibitor 2‐deoxyglucose (2‐DG) and the autophagy inhibitor chloroquine (CQ) through intraperitoneal injections on HK2‐addicted prostate cancers in animal models. The pharmacokinetic (PK) behaviors of these oral drugs after simultaneous oral administration have not been reported. We developed high‐performance liquid chromatography–tandem mass spectrometry (HPLC‐MS–MS) analytical methods for 2‐DG and the clinically favored drug hydroxychloroquine (HCQ) for sera samples. Using a jugular vein‐cannulated male rat model with serial blood collection before and after a single gavage dose of each drug alone or in combination, we examined their PK metrics for drug–drug interactions. The data demonstrated a rapid and complete separation of 2‐DG from common monosaccharides by HPLC‐MS–MS multi‐reaction monitoring. Application of the HPLC‐MS–MS 2‐DG and HCQ methods to sera samples of nine rats showed a peak time (Tmax) for 2‐DG of 0.5 h after 2‐DG alone or with HCQ and identical post‐peak half‐life of approximately 1 h. With a seemingly bi‐modal time course for HCQ, the Tmax for HCQ alone (1.2 h) was faster than that for the combination (2 h; p = .017). After combination dosing, the peak concentration (Cmax) and area under the curve (AUC0‐4h) of 2‐DG were decreased by 53.8% (p = .0004) and 53.7% (p = .0001), whereas AUC0‐8h for HCQ was decreased by 30.8% (p = .0279) from the respective single dosing. Without changing the mean residence time (MRT0‐∞) of each drug, the combination affected the apparent volume of distribution (Vd) and clearance (CL) of 2‐DG, and CL for HCQ without affecting its Vd. We observed significant negative PK interactions, probably at the intestinal absorption level, between 2‐DG and HCQ taken simultaneously by mouth. Future optimization efforts are warranted for their combination regimen for clinical translation.

7 March 2023 in Cannabis & Cannabinoid Research
Verified
Journal Article
Closed access
DKDeepkamal Karelia
Deepkamal Karelia
ZCZachary Corey
Zachary Corey
HWHaifeng Wang
Haifeng Wang
WRWesley M. Raup-Konsavage
Wesley M. Raup-Konsavage
KVKent E. Vrana
Kent E. Vrana
CJCheng Jiang
Cheng Jiang
Background: Our previous screening efforts with colorectal cancer cell lines suggested potential cannabinoid therapeutic leads for other solid cancers. Objectives: The aim of this study was to identify cannabinoid lead compounds that have cytostatic and cytocidal activities against prostate and pancreatic cancer cell lines and profile cellular responses and molecular pathways of select leads. Materials and Methods: A library of 369 synthetic cannabinoids was screened against 4 prostate and 2 pancreatic cancer cell lines with 48 h of exposure at 10 μM in medium with 10% fetal bovine serum using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) viability assay. Concentration titration of the top 6 hits was carried out to identify their concentration–response patterns and calculate IC 50 values. Three select leads were examined for cell cycle, apoptosis, and autophagy responses. The role of cannabinoid receptors (CB 1 and CB 2 ) and noncanonical receptors in apoptosis signaling was examined with selective antagonists. Results: Two independent screening experiments in each cell line detected growth inhibitory activities against all six or a majority of cancer cell lines for HU-331 (a known cannabinoid topoisomerase II inhibitor), (±)5-epi-CP55,940, and PTI-2, each previously identified in our colorectal cancer study. 5-Fluoro NPB-22, FUB-NPB-22, and LY2183240 were novel hits. Morphologically and biochemically, (±)5-epi-CP55,940 elicited caspase-mediated apoptosis of PC-3-luc2 (a PC-3 subline with luciferase) prostate cancer and Panc-1 pancreatic cancer cell lines, each the most aggressive of the respective organ site. The apoptosis induced by (±)5-epi-CP55,940 was abolished by the CB 2 antagonist, SR144528, but not modulated by the CB 1 antagonist, rimonabant, and GPR55 antagonist, ML-193, nor TRPV 1 antagonist, SB-705498. In contrast, 5-fluoro NPB-22 and FUB-NPB-22 did not cause substantial apoptosis in either cell line, but resulted in cytosolic vacuoles and increased LC3-II formation (suggestive of autophagy) and S and G 2 /M cell cycle arrests. Combining each fluoro compound with an autophagy inhibitor, hydroxychloroquine, enhanced the apoptosis. Conclusions: 5-Fluoro NPB-22, FUB-NPB-22, and LY2183240 represent new leads against prostate and pancreatic cancer cells in addition to the previously reported compounds, HU-331, (±)5-epi-CP55,940, and PTI-2. Mechanistically, the two fluoro compounds and (±)5-epi-CP55,940 differed regarding their structures, CB receptor involvement, and death/fate responses and signaling. Safety and antitumor efficacy studies in animal models are warranted to guide further R&D.

14 August 2023
Verified
Book Chapter
Closed access
PDF file
JLJunxuan Lu
Junxuan Lu
CJCheng Jiang
Cheng Jiang
MJMONIKA JOSHI
MONIKA JOSHI
JDJoseph J. Drabick
Joseph J. Drabick
The root of Angelica gigas [gigantus] Nakai (AGN) is a medicinal herbal in Korea. AGN root ethanolic extract dietary supplements are marketed for memory health and pain management. More than a dozen preclinical in vivo bioactivities of AGN extracts, including anti-cancer and sleep promotion, have been reported. Significant progress has been made in understanding the pharmacokinetics (PK) and metabolism of signature phytochemicals decursin and decursinol angelate and their botanical synthesis precursor and mammalian hepatic metabolite, decursinol, including human PK studies. This chapter summarizes PK and metabolism of pyranocoumarins and preclinical in vivo anti-cancer efficacy. For human clinical translation, significant challenges include sourcing of AGN extracts and product consistency. Human clinical trial design and AGN dose optimization are paramount in unlocking the anti-cancer potential. An open label Phase I/II trial is under way to estimate the effect size in a niche patient cohort with biochemically recurrent prostate cancer. <!----> <!----> <!----> <!---->